T1	Premise 1672 1724	Reported adverse events were similar between groups.
T2	Premise 1725 1788	A slight increase in transfusions was reported in the QW group.
T3	Claim 1789 1972	Darbepoetin alfa, when administered synchronously with chemotherapy, on an EDS appears to be similarly efficacious to darbepoetin alfa weekly dosing with no unexpected adverse events.
T4	Premise 1203 1321	Seventy-one percent of patients in the EDS group and 76% in the QW group achieved the target hemoglobin of â‰¥11.0 g/dL.
R1	Support Arg1:T1 Arg2:T3	
R2	Support Arg1:T4 Arg2:T3	
